Symmetricom®, Inc. (NASDAQ: SYMM), a worldwide leader in precision time and frequency technologies, today announced a new timing solution that meets the stringent microsecond accuracy requirements of Smart Grid substations. Specifically designed for substation operations, such as wide area measurement systems, traveling wave fault locators and sampled values, the Symmetricom SyncServer SGC-1500 Smart Grid Clock offers power utility companies accurate, secure and reliable timing and synchronization for their mission-critical operations. This means companies like Pacific Gas & Electric (PG&E) will be able to mitigate outages with real-time monitoring for grid stress, frequency instability, voltage instability and reliability margins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60168-symmetricom-next-generation-syncserver-sgc-1500-smart-grid-clock-utilities
As a new survey conducted online by Harris Interactive on behalf of Nutrisystem among over 3,000 U.S adults in December, indicates more than half of Americans (54 percent) are planning to make New Year’s resolutions to lose weight. Nutrisystem (NASDAQ: NTRI), the leading provider of home-delivered weight loss meal plans, is gearing up to help them succeed in keeping those resolutions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59643-nutrisystem-survey-weight-loss-new-year-s-resolutions
Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the European Commission has granted marketing authorization to Constella® (linaclotide 290mcg) for the symptomatic treatment of moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C) in adults . This approval follows the positive recommendation received from the European Committee for Medicinal Products for Human Use (CHMP) in September.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58658-almirall
To most technologists, cloud computing is about applications, servers, storage and connectivity. To Texas Instruments Incorporated (TI) (NASDAQ: TXN) it means much more. Today, TI is unveiling a BETTER way to cloud with six new multicore System-on-Chips (SoCs). Based on its award winning KeyStone architecture, TI’s SoCs are designed to revitalize cloud computing, inject new verve and excitement into pivotal infrastructure systems and, despite their feature rich specifications and superior performance, actually reduce energy consumption.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54044-texas-instruments-keystone-multicore-socs-revitalize-cloud-applications
The Brown Mackie College system of schools (“Brown Mackie College”), a college of Education Management Corporation (NASDAQ:EDMC), is adopting technology into education, converting students at its 28 schools nationwide to 100 percent e-textbooks and Apple iPad technology. Through the college’s Student Advantage Program, each incoming student will receive an iPad with the applications and textbooks necessary to make the technology a key part of their overall educational experience.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59095-brown-mackie-college-system-conversion-to-e-textbooks-ipad-nationwide
WebMD Health Corp. (NASDAQ: WBMD), the leading source of health information, today announced its new WebMD Pain Coach™ for iPhone, a unique free mobile application for consumers and patients living with chronic pain. As the leader in mobile health, WebMD provides trusted health information anytime and anywhere with its mobile web and applications for consumers and physicians. The new WebMD Pain Coach™ app builds on WebMD’s market-leading mobile applications through a holistic approach that helps users create a balanced lifestyle.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57975-webmd-launches-unique-new-mobile-app-for-those-living-with-chronic-pain
Dungeon Rampage, the online game from developer and publisher Rebel Entertainment, an operating business of IAC (NASDAQ: IACI), officially launches today with new and expanded free-to-play content on Facebook Platform, dedicated site DungeonRampage.com and online gaming portal Kongregate.com.
To celebrate the launch, Rebel Entertainment is hosting a “Founders’ Week,” in which players can sign up on any platform between now and September 11 to receive special in-game bonuses, including an exclusive character style, customizable profile add-ons and more.
To view Multimedia News Release, go to http://www.multivu.com/mnr/57854-rebel-entertainment-dungeon-rampage-online-arcade-style-multiplayer-game
Activision Blizzard, Inc., the largest third-party interactive entertainment software publisher (Nasdaq: ATVI), and Tencent Holdings Limited, a leading Internet services provider in China (SEHK: 00700), today announced a strategic relationship to bring Call of Duty Online to Chinese game players.
Call of Duty Online has been in development by Activision Publishing, Inc., a wholly owned subsidiary of Activision Blizzard, for approximately two years. Under the multi-year agreement with Activision Publishing, Tencent has the exclusive license to operate Call of Duty Online in mainland China. The game is free-to-play and monetized through the sales of in-game items.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56961-activision-and-tencent-bring-call-of-duty-franchise-to-china
If your spider-senses are tinglin’, it’s because The Amazing Spider-Man™video game has web-slung its way onto retail store shelves today in North America, and will be available in Europe on June 29th. From Activision Publishing, Inc., a wholly owned subsidiary of Activision Blizzard, Inc. (Nasdaq: ATVI), and Marvel Entertainment, The Amazing Spider-Man video game serves as an epilogue story to this summer’s upcoming blockbuster feature film, heralding Spidey’s return to a free-roaming Manhattan as players take the role of a young Peter Parker discovering his newfound powers and Super Hero responsibilities. The Amazing Spider-Man video game is available on the Xbox 360® video game and entertainment system from Microsoft, PlayStation®3 computer entertainment system, the Wii™ system from Nintendo, Nintendo 3DS™ and Nintendo DS™ handheld systems.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56937-activision-marvel-the-amazing-spider-man-new-video-game
Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that the Light Study, a long-term research study of Contrave® (naltrexone SR/bupropion SR), a new, investigational drug being evaluated for weight loss, has begun enrolling patients at clinical sites throughout the United States. The Light Study is designed to assess the cardiovascular health outcomes of Contrave.
Nearly 93 million Americans are affected by obesity, and that number is predicted to increase to 120 million Americans within the next five years. More than one-third of adults in the United States are affected by obesity. Obesity increases the risk of heart disease, type 2 diabetes, some types of cancer, sleep apnea, and a variety of other conditions. Medical research suggests that losing just five percent of your body weight can significantly improve your health and reduce the risk of complications from type 2 diabetes and heart disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56480-lightstudy
Walgreens (NYSE, NASDAQ: WAG) and the National Urban League (NUL), today announced the launch of the Walgreens Way to Well Health Tour with National Urban League as a charitable component of the Walgreens Way to Well Commitment®. The national tour will provide free health resources to residents in urban and minority communities who experience disproportionately higher rates of preventable disease. The service is free and insurance will not be billed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54971-walgreens-way-to-well-health-tour-with-nul
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
